Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab
- PMID: 35970248
- DOI: 10.1016/j.amjms.2022.07.007
Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a multisystem antineutrophil cytoplasmic antibody (ANCA) positive vasculitis, characterized by the presence of chronic rhinosinusitis, asthma and prominent peripheral blood eosinophilia. Although the most commonly involved organ is the lung, followed by the skin, EGPA can affect any organ system. Herein, we present the complicated case of an 18-year-old male patient with severe life-threatening EGPA, with central nervous system, cardiac and gasterointestinal involvement, which was resistant to initial treatment with glucocorticoids and cyclophosphamide. The patient responded well, achieving complete remission after the addition of rituximab and mepolizumab to glucocorticoids and cyclophosphamide.
Keywords: Cyclophosphamide; Eosinophilic granulomatosis with polyangiitis; Glucocorticoids; Mepolizumab; Rituximab.
Copyright © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest There are no conflict sof interest regarding this manuscript.
Similar articles
-
MPO-ANCA-positive eosinophilic granulomatosis with polyangiitis complicated by alveolar haemorrhage treated with mepolizumab as an induction therapy: Case report.Mod Rheumatol Case Rep. 2025 Jul 25;9(2):rxae088. doi: 10.1093/mrcr/rxae088. Mod Rheumatol Case Rep. 2025. PMID: 39707621
-
Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review.Rheumatol Int. 2022 Nov;42(11):2069-2076. doi: 10.1007/s00296-021-04950-z. Epub 2021 Jul 21. Rheumatol Int. 2022. PMID: 34287685 Review.
-
Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis.Pediatr Pulmonol. 2023 Mar;58(3):973-979. doi: 10.1002/ppul.26249. Epub 2022 Dec 5. Pediatr Pulmonol. 2023. PMID: 36404638
-
A case of subarachnoid haemorrhage associated with MPO-ANCA-positive eosinophilic granulomatosis with polyangiitis, successfully treated with glucocorticoid, cyclophosphamide, and mepolizumab.Mod Rheumatol Case Rep. 2024 Jul 8;8(2):310-313. doi: 10.1093/mrcr/rxad071. Mod Rheumatol Case Rep. 2024. PMID: 38109745
-
[Eosinophilic granulomatosis with polyangiitis : Update on classification and management].Z Rheumatol. 2022 May;81(4):286-299. doi: 10.1007/s00393-021-01153-6. Epub 2022 Jan 24. Z Rheumatol. 2022. PMID: 35075511 Review. German.
Cited by
-
Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.J Leukoc Biol. 2024 Jul 25;116(2):307-320. doi: 10.1093/jleuko/qiae051. J Leukoc Biol. 2024. PMID: 38457125 Free PMC article. Review.
-
Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis.Curr Cardiol Rep. 2025 Jul 9;27(1):109. doi: 10.1007/s11886-025-02258-z. Curr Cardiol Rep. 2025. PMID: 40632386 Free PMC article. Review.
-
Relapse of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Despite Maintenance Treatment With Low-Dose Mepolizumab.Respirol Case Rep. 2025 May 7;13(5):e70186. doi: 10.1002/rcr2.70186. eCollection 2025 May. Respirol Case Rep. 2025. PMID: 40337294 Free PMC article.
-
The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.Rheumatol Int. 2023 Jul;43(7):1245-1252. doi: 10.1007/s00296-023-05326-1. Epub 2023 Apr 21. Rheumatol Int. 2023. PMID: 37085573 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical